DDInter598 DDInter1435
Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Doxycycline {u} (Compound) resembles {v} (Compound) Tigecycline
Doxycycline {u} (Compound) resembles {v} (Compound) Tetracycline
Doxycycline {u} (Compound) treats {v} (Disease) malaria
Doxycycline {u} (Compound) binds {v} (Gene) MMP1
Doxycycline {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
Doxycycline {u} (Compound) is included by {v} (Pharmacologic Class) Tetracyclines
Doxycycline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lithium carbonate
Doxycycline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Torasemide
Doxycycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenoxymethylpenicillin
Doxycycline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin human
Doxycycline (Compound) resembles Tigecycline (Compound)
Doxycycline (Compound) resembles Tetracycline (Compound)
Doxycycline (Compound) treats malaria (Disease)
Doxycycline (Compound) binds MMP1 (Gene)
Doxycycline (Compound) palliates chronic obstructive pulmonary disease (Disease)
Doxycycline (Compound) is included by Tetracyclines (Pharmacologic Class)
Doxycycline may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Doxycycline may cause a minor interaction that can limit clinical effects when taken with Torasemide
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Phenoxymethylpenicillin
Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Insulin human